David P Lerner

US Patent:

7045673, May 16, 2006

Filed:

Dec 8, 1999

Appl. No.:

09/857906

Inventors:

Christopher D. Batich - Gainesville FL, US
Bruce A Mast - Gainesville FL, US
Gregory Schultz - Gainesville FL, US
Gerald M. Olderman - New Bedford MA, US
David S. Lerner - Boca Raton FL, US

Assignee:

Quick-Med Technologies, Inc. - Gainesville FL
University of Florida Research Foundation, Inc. - Gainesville FL

International Classification:

A61F 13/00

US Classification:

602 48, 602 42, 602 43, 424443, 424447

Abstract:

Absorbent dressings, including highly-absorbent dressings having antimicrobial polymer attached thereto via non-siloxane bonds are disclosed. Bandages (i. e. wound dressing), sanitary napkins and the like are useful applications for the intrinsically bactericidal absorbent dressings whose method of manufacture and use are disclosed and claimed.

US Patent:

7709694, May 4, 2010

Filed:

Sep 28, 2001

Appl. No.:

09/965740

Inventors:

Christopher D. Batich - Gainesville FL, US
Gregory Schultz - Gainesville FL, US
Bruce A. Mast - Gainesville FL, US
Gerald M. Olderman - New Bedford MA, US
David S. Lerner - Boca Raton FL, US
William Toreki - Gainesville FL, US

Assignee:

Quick-Med Technologies, Inc. - Gainesville FL
University of Florida Research Foundation, Inc. - Gainesville FL

International Classification:

A61F 13/00

US Classification:

604360, 602 48, 427 231

Abstract:

This invention relates to methods and compositions for materials having a non-leaching coating that has antimicrobial properties. The coating is applied to substrates such as gauze-type wound dressings. Covalent, non-leaching, non-hydrolyzable bonds are formed between the substrate and the polymer molecules that form the coating. A high concentration of anti-microbial groups on multi-length polymer chains and relatively long average chain lengths, contribute to an absorbent or superabsorbent surface with a high level antimicrobial effect.

US Patent:

20060165617, Jul 27, 2006

Filed:

Apr 3, 2006

Appl. No.:

11/278461

Inventors:

David Lerner - Gainesville FL, US
Gregory Schultz - Gainesville FL, US

Assignee:

Quick-Med Technologies, Inc. - Gainesville FL

International Classification:

A61K 8/97
A61K 31/56
A61K 31/704

US Classification:

424059000, 424074000, 514171000, 514026000

Abstract:

A cosmetic topical formulation and method are directed toward diminishing skin wrinkling and fine lines and improving skin tone. It contains a matrix metalloproteinase inhibitor, MMPI, e.g. batimastat or marimastat, and a natural estrogen, e.g., a true estrogen compound, such as 17-beta estradiol, or an estrogen-like steroid (such as various phytoestrogens found in herbal preparations). Exemplary phytoestrogens include triterpenoid glycosides. Certain compositions of this invention are useful for minimizing photodamage to skin, while in other embodiments, a composition according to this invention is useful to prevent or minimize the adverse effects on skin induced by cigarette smoking. The method of the invention involves administering the components such as in a dermal preparation.

US Patent:

20080139512, Jun 12, 2008

Filed:

Jan 30, 2006

Appl. No.:

11/343024

Inventors:

David S. Lerner - Gainesville FL, US
Gregory Schultz - Gainesville FL, US

Assignee:

Quick-Med Technologies, Inc. - Gainesville FL
University of Florida Research Foundation, Inc. - Gainesville FL

International Classification:

A61K 31/665
A61K 31/573
A61K 31/405
A61K 31/137
A61K 31/095

US Classification:

514100, 514171, 514420, 514649, 514706

Abstract:

The invention pertains to compositions and methods to treat the adverse effects of mustard chemicals and other toxic compounds, such as chemical warfare agents, exposure to which normally induces vesicating type response in mammals. In a rodent eye model at fixed concentrations of such a vesicant, compositions comprising a matrix metalloproteinase inhibitor, MMPI, a significant reduction in morbidity is achieved. with increased concentrations of the compositions of this invention, as compared with vehicle alone. Furthermore, compositions comprising the MMPI and in addition, an anti-inflammatory compound, in a vehicle appropriate to the type of tissue damage to be protected against from vesicant exposure, achieves both reduction in total tissue damage and inflammation, as compared with anti-inflammatory composition alone. Chemicals having more than one property, such as MMPI and AIA properties, are also disclosed.